Evidence map›Paper›PMID 22664637›Full record

ArticleBiochimie2013

A model of flux regulation in the cholesterol biosynthesis pathway: Immune mediated graduated flux reduction versus statin-like led stepped flux reduction.

Steven Watterson, Maria Luisa Guerriero, Mathieu Blanc, Alexander Mazein, Laurence Loewe, Kevin A Robertson, Holly Gibbs, Guanghou Shui, Markus R Wenk, Jane Hillston and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Biochimie, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Computationally Modeling Lipid Metabolism and Aging: A Mini-review.Computational and structural biotechnology journal · 2015
    Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Steven WattersonDivision of Pathway Medicine, University of Edinburgh Medical School, Chancellor's Building, 49 Little France Crescent, Edinburgh, Scotland, United Kingdom. s.watterson@ed.ac.uk
Maria Luisa Guerriero
Mathieu Blanc
Alexander Mazein
Laurence Loewe
Kevin A Robertson
Holly Gibbs
Guanghou Shui
Markus R Wenk
Jane Hillston
Peter Ghazal
University of Edinburgh · GBNational University of Singapore · SG

Funding

Biotechnology and Biological Sciences Research Council BB/D019621/1Wellcome Trust WT066784
6 · The paper itself

Abstract

The cholesterol biosynthesis pathway has recently been shown to play an important role in the innate immune response to viral infection with host protection occurring through a coordinate down regulation of the enzymes catalysing each metabolic step. In contrast, statin based drugs, which form the principle pharmaceutical agents for decreasing the activity of this pathway, target a single enzyme. Here, we build an ordinary differential equation model of the cholesterol biosynthesis pathway in order to investigate how the two regulatory strategies impact upon the behaviour of the pathway. We employ a modest set of assumptions: that the pathway operates away from saturation, that each metabolite is involved in multiple cellular interactions and that mRNA levels reflect enzyme concentrations. Using data taken from primary bone marrow derived macrophage cells infected with murine cytomegalovirus or treated with IFNγ, we show that, under these assumptions, coordinate down-regulation of enzyme activity imparts a graduated reduction in flux along the pathway. In contrast, modelling a statin-like treatment that achieves the same degree of down-regulation in cholesterol production, we show that this delivers a step change in flux along the pathway. The graduated reduction mediated by physiological coordinate regulation of multiple enzymes supports a mechanism that allows a greater level of specificity, altering cholesterol levels with less impact upon interactions branching from the pathway, than pharmacological step reductions. We argue that coordinate regulation is likely to show a long-term evolutionary advantage over single enzyme regulation. Finally, the results from our models have implications for future pharmaceutical therapies intended to target cholesterol production with greater specificity and fewer off target effects, suggesting that this can be achieved by mimicking the coordinated down-regulation observed in immunological responses.

Indexed as

Models, BiologicalCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsImmunityImmunity, InnateInterferon-gammaMuromegalovirusReproducibility of ResultsCholesterolHydroxymethylglutaryl-CoA Reductase InhibitorsInterferon-gamma

Identifiers

PMID22664637
PMCPMC3585962
OpenAlexW2109756838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.